Clene (NASDAQ:CLNN) & Alberton Acquisition (NASDAQ:ALAC) Financial Survey

Clene (NASDAQ:CLNN) and Alberton Acquisition (NASDAQ:ALAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Clene has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, Alberton Acquisition has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

Profitability

This table compares Clene and Alberton Acquisition’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clene N/A -2.46% -2.20%
Alberton Acquisition N/A -0.60% -0.54%

Analyst Recommendations

This is a summary of recent recommendations for Clene and Alberton Acquisition, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene 0 0 3 0 3.00
Alberton Acquisition 0 0 0 0 N/A

Clene presently has a consensus price target of $23.67, indicating a potential upside of 224.20%. Given Clene’s higher probable upside, equities research analysts plainly believe Clene is more favorable than Alberton Acquisition.

Earnings & Valuation

This table compares Clene and Alberton Acquisition’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clene N/A N/A $270,000.00 N/A N/A
Alberton Acquisition N/A N/A $2.09 million N/A N/A

Institutional and Insider Ownership

62.6% of Clene shares are held by institutional investors. Comparatively, 28.6% of Alberton Acquisition shares are held by institutional investors. 3.6% of Clene shares are held by insiders. Comparatively, 21.8% of Alberton Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Alberton Acquisition beats Clene on 6 of the 9 factors compared between the two stocks.

Clene Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.

Alberton Acquisition Company Profile

Alberton Acquisition Corporation does not have significant operations. It intends to engage in a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.